ENDEAVOR

to Evaluate the Efficacy and Safety of AZD4831 Administered for up to 48 Weeks in Participants with Heart Failure With Left Ventricular Ejection Fraction > 40%

Stage: klaar
Medicine: AZD4831
Population: Hartfalen
Phase: III
First Patient In: 22 September 2022
Last Patient In: 31 March 2023
Last Patient Last Visit: 31 March 2024

Study Director

dr. S. van Wijk

Cardioloog

Office Contact

S. Jansen

Studiemanager